DOUGLAS LANGEMEIER: Open Payments
NPI 1528076171 · NEBRASKA CITY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$312 in 20 payments from 8 companies in 2025. Trend: 2023 $263 · 2024 $428 · 2025 $312
Food & beverage: $312
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 9 | $132 |
| Novo Nordisk Inc | 3 | $51 |
| Novartis Pharmaceuticals Corporation | 2 | $37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| ABBVIE INC. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
| Amgen Inc. | 1 | $14 |
Products named: JARDIANCE, MOUNJARO, LEQVIO, Rybelsus, XIFAXAN, VRAYLAR, OPSUMIT, Ozempic.
Industry payments across NE — which companies pay providers there.
